When a high-throughput screen, a natural product isolation, or a machine learning model identifies a molecule that binds to a disease target, the drug discovery process has only just begun. These initial molecules, termed "hits" or "leads," are rarely ready for clinical use; they are merely structural starting points. As Safia Manzoor et al. note in their study of microtubule depolymerizing agents in Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance, initial hits typically require extensive refinement to overcome off-target toxicities and achieve the potency required for human trials. Lead optimization is the iterative process of reshaping these molecular templates to maximize therapeutic efficacy while ensuring safety, solubility, and stability inside a living organism.
Driving Affinity from Micromolar to Nanomolar Potency
Why do initial hits fail to perform at low concentrations? Often, their binding affinity is in the micromolar range, meaning a high concentration of the drug is required to achieve the desired biological effect. In clinical settings, high doses increase the risk of off-target toxicity. To solve this, medicinal chemists optimize the molecular interface to achieve nanomolar or sub-nanomolar potency, ensuring the drug works effectively at minimal doses.
This optimization relies on tailoring the molecule's shape to exploit specific sub-pockets within the target protein. For instance, the authors of Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study demonstrated that modifying small molecule interactions to fit precisely within specific hydrophobic sub-pockets (such as those containing Met165 and Met49) can yield inhibitors that outperform initial benchmarks by several hundredfold.
Similarly, Xiaoyan Tian et al. emphasize in Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation that computational screening leads must undergo targeted structural modifications to transition from raw hits to highly potent candidates. When dealing with weak binders, such as the micromolar-affinity molecules identified by Gabriella T. Heller et al. in Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease, optimizing the association rate becomes a primary lever for increasing overall potency.
Overcoming Pharmacokinetic and Metabolic Barriers
A molecule can possess exceptional binding affinity in a test tube, yet fail completely in vivo if it cannot reach the target tissue. Natural products and raw screening hits frequently suffer from poor absorption, high metabolic clearance, or low solubility.
The authors of The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun highlight this challenge, noting that natural bioactive monomers often require structural optimization to survive metabolic degradation in the liver. Optimization involves systematically modifying functional groups to balance lipophilicity and water solubility. As Dong Ma et al. observe in Design, step-economical diversity-oriented synthesis of an N-heterocyclic library containing a pyrimidine moiety: discovery of novel potential herbicidal agents, adjusting these properties is essential for maximizing biological impact while minimizing off-target toxicities. For oral medications, the stakes are even higher; Emna Harigua‐Souiai demonstrated in Identification of novel leishmanicidal molecules by virtual and biochemical screenings targeting Leishmania eukaryotic translation initiation factor 4A that modifying cholestanol-based structures to enhance solubility is a prerequisite for developing viable oral formulations.
Scaffold Hopping and Fragment Elaboration
Sometimes, the core architecture of a lead compound is inherently flawed—perhaps due to toxicity or patent restrictions—even if its side chains form perfect bonds with the target protein. In these cases, researchers employ "scaffold hopping" to replace the central core while preserving the spatial orientation of the interacting groups.
To automate this complex task, Chao Hu et al. introduced a deep learning framework in ScaffoldGVAE: scaffold generation and hopping of drug molecules via a variational autoencoder based on multi-view graph neural networks that uses variational autoencoders and graph neural networks to generate alternative core structures that maintain target binding while improving safety and stability.
[Weak Fragment] ---> [Fragment Elaboration / Growing] ---> [High-Affinity Lead]
|
+------------> [Scaffold Hopping / Core Swap] ---> [Optimized Candidate]
A complementary strategy is fragment-based drug discovery (FBDD), which starts with exceptionally small molecular fragments that bind weakly but cleanly to the target. Pooja Gupta illustrates in A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis that while these initial fragments provide invaluable structural roadmaps of binding pockets, they possess low intrinsic potency and must be chemically grown or merged into larger, high-affinity leads. This progression from millimolar fragments to micromolar or nanomolar leads, as described by Jordi Doijen et al. in A New Fragment‐Based Pharmacophore Virtual Screening Workflow Identifies Potent Inhibitors of SARS‐CoV‐2 NSP13 Helicase, represents one of the most rigorous applications of structure-guided lead optimization.